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A spliced latency-associated VZV transcript maps
antisense to the viral transactivator gene 61
Daniel P. Depledge 1,7, Werner J.D. Ouwendijk2, Tomohiko Sadaoka 3, Shirley E. Braspenning2,
Yasuko Mori3, Randall J. Cohrs4,5, Georges M.G.M. Verjans2,6 & Judith Breuer 1
Varicella-zoster virus (VZV), an alphaherpesvirus, establishes lifelong latent infection in the
neurons of >90% humans worldwide, reactivating in one-third to cause shingles, debilitating
pain and stroke. How VZV maintains latency remains unclear. Here, using ultra-deep virus-
enriched RNA sequencing of latently infected human trigeminal ganglia (TG), we demon-
strate the consistent expression of a spliced VZV mRNA, antisense to VZV open reading
frame 61 (ORF61). The spliced VZV latency-associated transcript (VLT) is expressed in
human TG neurons and encodes a protein with late kinetics in productively infected cells
in vitro and in shingles skin lesions. Whereas multiple alternatively spliced VLT isoforms
(VLTly) are expressed during lytic infection, a single unique VLT isoform, which speciﬁcally
suppresses ORF61 gene expression in co-transfected cells, predominates in latently VZV-
infected human TG. The discovery of VLT links VZV with the other better characterized
human and animal neurotropic alphaherpesviruses and provides insights into VZV latency.
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During primary infection, neurotropic alphaherpesviruses(αHVs) gain access to neurons in sensory, cranial andautonomic ganglia to establish a lifelong latent infection
from which they can reactivate to cause debilitating disease1. For
the best-studied αHVs, including herpes simplex virus types 1
and 2 (HSV-1 and HSV-2), pseudorabies virus and bovine her-
pesvirus 1 (BHV-1), viral latency has been shown to be
accompanied by the expression of a single or restricted set of
latency-associated transcripts (LATs)2–6. These transcripts map
antisense to the gene encoding the conserved multifunctional
HSV infected cell protein 0 (ICP0), to which varicella-zoster virus
(VZV) open reading frame 61 (ORF61) is homologous, which
besides inhibiting intrinsic cellular antiviral responses is the
major transcriptional transactivator of lytic viral genes required
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for reactivation of latent HSV2–10. While the function of the
LATs remains uncertain (reviewed in ref. 11), there is mounting
evidence from work on HSV-1, HSV-2 and BHV-1 that LATs
induce generalized transcriptional and/or translational repres-
sion12, and several studies have shown that LAT-encoded miR-
NAs (e.g., miR-H2, in HSV-1) or proteins (e.g., BHV-1 latency-
related protein) target viral mRNAs including ICP013–15.
The exception has been VZV, a human-restricted αHV and
causative agent of varicella and herpes zoster, for which no
latency transcript mapping antisense to its ICP0 homologue
ORF61 has been described1,16–18. While the absence of a cano-
nical latency transcript in VZV may represent a fundamental
difference in the evolution and biology of this virus, it is notable
that a putative LAT, antisense to ORF61, has also been described
for simian varicella virus (SVV), the varicellovirus most closely
related to VZV. However, neither the transcript nor its function
in SVV infection have been studied in detail7,8.
Like other herpesviruses, lytic VZV infection is characterized
by full viral gene expression occurring with temporally linked
immediate-early (IE), early (E) and late (L) kinetics to generate
infectious virus progeny19,20. By contrast, VZV gene expression
during latency remains poorly deﬁned16,18,21–23. This is largely
due to the lack of appropriate animal24 and, until recently,
in vitro25,26 models, which accurately mimic VZV pathogen-
esis24–26. VZV latency has been extensively studied in cadaveric
human trigeminal ganglia (TG), a prominent anatomic site of
both HSV-1 and VZV latency, yielding conﬂicting results as to
which VZV transcripts and proteins are expressed27. Whereas
viral protein detection by immunohistochemistry (IHC) can lar-
gely be attributed to non-speciﬁc binding of anti-VZV antibody
preparations23,28, the time interval between death and TG spe-
cimen processing (post-mortem interval, PMI) determines the
number and quantity of VZV transcripts detected16,18,22. Using
PCR primers targeting all canonical VZV genes, only the lytic
gene ORF63 is occasionally detected in TGs with PMI < 9 h18,
whereas multiple viral transcripts of different kinetic classes are
detected in human TGs with PMI > 9 h16,18,22 and also frequently
in animal models29,30.
Here we describe the identiﬁcation of a VZV latency-associated
transcript (VLT), consistently detected in VZV and HSV-1 co-
infected human TG that lies antisense to ORF61. Although
multiple alternatively spliced transcripts are present during pro-
ductive infection, the unique VLT isoform that supresses ORF61
gene transcription in co-transfected cells predominates during
latency. The discovery of VLT uniﬁes the VZV latent viral
transcription programme with that of other better-characterized
human and animal neurotropic αHVs while removing long-
standing barriers to understanding VZV latency.
Results
Exclusive detection of HSV-1 LAT and miRNAs in human TG.
We ﬁrst validated our experimental approach by sequencing
enriched and unenriched viral transcripts from lytically VZV- or
HSV-1-infected human retinal pigmented epithelial (ARPE-19)
cells to demonstrate detection of all currently annotated VZV and
HSV-1 genes at high speciﬁcity and sensitivity (Figs. 1 and 2 and
Supplementary Fig. 1). RNA-Seq of unenriched RNA libraries
from two latently VZV and HSV-1 co-infected human TGs
(donors 1 and 2, Supplementary Tables 1 and 2), enriched for
polyadenylated transcripts or ribosomal RNA-depleted total RNA
(Supplementary Fig. 2), conﬁrmed the presence of the stable 1.5/
2.0-kb LAT-derived introns, the hallmark of HSV-1 latency6.
Enrichment for polyadenylated HSV-1 sequences in the same
TGs and ﬁve additional dually latently infected TGs (donors 1–7,
Supplementary Tables 1 and 2) revealed both LAT introns and
the near-complete 8.3-kb full-length LAT transcript from which
they derive but no other viral transcripts (Fig. 1 and Supple-
mentary Fig. 3). The latency-associated miRNAs (mir-H2, mir-
H3, mir-H4, mir-H6, mir-H7 and mir-H14)13 were also detected
in three TGs (donors 1, 3 and 5) selected for and analysed by
miRNA sequencing of unenriched RNA libraries (Supplementary
Fig. 4). These data illustrate the high speciﬁcity and sensitivity of
our target-enriched RNA-Seq methodology and clearly demon-
strate that the HSV-1 latency transcriptome in human TG is
limited to the LATs and encoded miRNAs.
Identiﬁcation of a spliced VZV latency-associated transcript.
While no VZV transcripts could be identiﬁed in non-enriched
TG RNA samples (Supplementary Fig. 5), enrichment for VZV
sequences in polyadenylated RNA revealed the presence of a
novel 496-nucleotide multi-exon transcript located antisense to
ORF61 in all the seven TGs analysed (donors 1–7; Fig. 2, Sup-
plementary Figs. 5 and 6 and Supplementary Tables 1 and 2).
Manual inspection of the VZV sequence read data, combined
with de novo transcript reconstruction, revealed ﬁve distinct
exons (Figs. 2 and 3), two of which encode cleavage factor I-
binding motifs (TGTA), while the most 3’ exon contained a
canonical polyadenylation signal site (AAUAAA) (Fig. 3). We
term this the VZV latency-associated transcript (VLT) and sub-
sequently conﬁrmed that VLT nucleotides 40–460 (spanning
exons 1–5) are detected as a single transcript using cDNA
obtained from the ﬁve TGs with the highest VLT expression
(Fig. 4a and Supplementary Table 1). Except for ORF63 tran-
scripts detected in six of the seven TGs (donors 2–7), no other
VZV transcripts (Fig. 2b and Supplementary Fig. 6) or miRNAs
were detected in human TGs.
Distinct VLT mRNA isoforms expressed during lytic infection.
The VLT locus was also transcribed in lytically VZV-infected
ARPE-19 and MeWo cells (Figs. 2b and 4c and Supplementary
Fig. 6), enabling rapid ampliﬁcation of cDNA ends (RACE) to
determine 5’ and 3’ transcript boundaries. Unlike the single VLT
isoform detected in latently VZV-infected human TG (Figs. 2
and 4a, b), gene transcription from the VLT locus appears
Fig. 1 HSV-1 transcriptome proﬁle during lytic and latent infection. Strand-speciﬁc mRNA-seq of lytically HSV-1-infected ARPE-19 cells and seven latently
HSV-1-infected human trigeminal ganglia (TG) (Supplementary Table 1). a Circos plots of the HSV-1 genome [purple band; sense and antisense open
reading frames (ORFs) indicated as blue and red blocks, respectively], the latency associated transcripts (LATs) indicated as green blocks, with internal
tracks revealing the lytic (left) and latent (right) transcriptomes using unenriched (grey tracks) and HSV-1-enriched (black tracks) libraries. Lytic
transcriptomes were proﬁled using HSV-1-infected ARPE-19 cells. Latent HSV-1 transcriptomes are proﬁled from seven TGs, with each track depicting a
single specimen. Peaks facing outward from the centre indicate reads mapping to the sense strand, while peaks facing inward originate from the antisense
strand. The y axis is scaled to maximum read depth per library in all cases. b Linear representation of the HSV-1 LAT genomic region (green blocks in a),
with blue and yellow tracks depicting HSV-1-enriched mRNA-Seq reads originating from the sense and antisense strand, respectively. Unenriched mRNA-
Seq tracks for ARPE-19 cells, and TGs 1 and 2, are superimposed and shown in light blue (sense) or yellow (antisense), with overlapping regions in
medium-blue and orange, respectively. HSV-1 genome coordinates are shown the HSV-1 reference strain 17 (NC_001806.2); Previously described HSV-1
ORFs within this locus (red boxes), miRNAs (orange blocks), LAT-encoded ORFs (green blocks), LAT-encoded small RNAs (dark red blocks) and LAT
(blue boxes) are scaled representatively. . Paired-end read data sets were generated with read lengths of 2 × 34 bp (ARPE-19) or 2 × 76 bp (TG1 and TG2)
or 2 × 151 bp (TG3–TG7)
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extremely complex during lytic VZV infection of ARPE-19 and
MeWo cells (Figs. 2b and 4c, respectively), with additional
upstream exons or alternative splicing in exons 3 and 4. Reverse
transcriptase–quantitative PCR (RT-qPCR) did not detect any of
the three most abundant lytic VLT (hereafter VLTly) isoforms
(each VLTly isoform uses a different upstream exon) in latently
VZV-infected TGs (Fig. 4d). Neither additional upstream exons
nor alternative splicing of exons 3 and/or 4 were evident in the
RNA-Seq data of human TG-derived VZV RNA. Thus a single
unique VLT isoform is selectively expressed in latently VZV-
infected human TG with short PMI.
VZV latency is characterized by VLT and ORF63 expression.
To conﬁrm that VLT expression is a general feature of VZV
latency, we analysed TG specimens from 18 individuals (donors
1–18; Supplementary Table 1) for the presence of VZV and HSV-
1 DNA and transcripts by qPCR and RT-qPCR, respectively.
Thirteen TG were co-infected with VZV and HSV-1, while the
remaining TG contained only VZV (donors 10 and 12) or HSV-1
(donors 16–18), (Supplementary Table 1). Fourteen of the 15
(93%) VZV nucleic acid-positive (VZVPOS) TGs expressed VLT
and 9 of the 15 (60%) VZVPOS TGs co-expressed ORF63 mRNA
at lower levels relative to VLT (Fig. 4e, Supplementary Fig. 7a and
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Supplementary Table 1). VLT levels correlated signiﬁcantly with
ORF63 transcript levels (Fig. 4f and Supplementary Fig. 7b) but
not with VZV DNA load or PMI excluding the possibility of viral
reactivation after death (Supplementary Fig. 7c, d)18. Next, we
investigated the expression and localization of VLT, and as a
control, VZV ORF63 transcript, in latently VZV-infected TGs (n
= 12) and two VZV naive human fetal dorsal root ganglia (DRG)
by in situ hybridization (ISH). VLT and ORF63 transcripts were
localized to both the neuronal nucleus and cytoplasm of distinct
neurons in latently VZV-infected TG but not in uninfected DRG
(Fig. 4g–j and Supplementary Fig. 8). Signiﬁcantly more (p=
0.04; paired Student’s t-test) TG neurons expressed VLT than
ORF63 transcript (Fig. 4g). RNase but not DNase treatment
abolished ORF63- and VLT-speciﬁc ISH staining (Supplementary
Fig. 8), conﬁrming detection of VZV transcripts and not viral
genomic DNA. In agreement with previous studies, both RT-
qPCR and ISH data (Supplementary Table 1 and Supplementary
Fig. 9) revealed a much higher abundance and prevalence of
HSV-1 LAT compared to VLT and VZV ORF63 RNA in human
TG specimens31.
VLT encodes a protein that is expressed in lytic infection. In
silico translation of the VLT isoform expressed in human TG
predicted a 136 amino acid protein (pVLT), with a start codon
and polyadenylation site/stop codon in exons 2 and 5, respec-
tively (Fig. 3b). A polyclonal pVLT-speciﬁc antibody generated
against the ﬁrst 19 N-terminal residues of pVLT (Fig. 3c) con-
ﬁrmed pVLT expression in VLT-transfected ARPE-19 cells
(Fig. 5a). In lytically VZV-infected ARPE-19 cells, pVLT is co-
expressed by cells expressing ORF62 protein (IE62) and glyco-
protein E but not by uninfected cells (Fig. 5b). The kinetic class of
VLTly was determined by RT-qPCR in VZV-infected ARPE-19
cells cultured in the presence or absence of phosphonoformic acid
(PFA), a broad-spectrum herpesvirus DNA polymerase inhi-
bitor32. Whereas no effect on ORF61 (IE gene) and ORF29 (E
gene) transcription was observed, ORF49 (leaky L gene) tran-
scription was markedly reduced in PFA-treated VZV-infected
cells (Fig. 5c). PFA blocked VLTly expression completely (Fig. 5c),
demonstrating that VLTly transcription follows a true late kinetic
pattern in vitro. Finally, shingles skin biopsies were assayed for
the expression of VLTly and pVLT. ISH revealed VLTly expres-
sion throughout the affected epidermis and dermis surrounding
skin vesicles (Fig. 5d), while IHC analyses of consecutive sections
for VZV ORF63 protein (IE63) and pVLT indicated co-
expression in the same skin areas but not in healthy control
skin (Fig. 5e and Supplementary Fig. 10). Neither pVLT- nor
IE63-speciﬁc IHC signal was detected in latently VZV-infected
human TG sections.
VLT represses ORF61 expression in co-transfected cells.
Because VLT is antisense to VZV gene ORF61, a major viral
transactivator and αHV ICP0 homologue33, we tested whether
VLT affects ORF61 expression. ARPE-19 cells were co-
transfected with four plasmids, each containing a single coding
VZV sequence (ORFs 61, 62 and 63 and the mature, spliced
coding sequence of VLT) under the control of a chicken beta-
actin (for ORF61, ORF63 and VLT) or human cytomegalovirus
promoter (for ORF62). VLT expression signiﬁcantly reduced
ORF61, but not ORF62 and ORF63 transcript levels, in co-
transfected cells (Fig. 6a and Supplementary Fig. 11). Western
blot analysis conﬁrmed that VLT diminishes IE61 but not IE62,
IE63 and α-tubulin protein abundance in co-transfected cells
(Fig. 6b). Mutation of the pVLT start codon within exon 2
(Fig. 3b) from ATG to ATA resulted in loss of pVLT expression
in transfected ARPE-19 cells (Fig. 6b and Supplementary Fig. 12)
but did not abolish the inhibitory effect of VLT on ORF61
transcription and protein (IE61) expression in co-transfected cells
(Fig. 6b). The data implicate VLT, but not pVLT, in the selective
repression of VZV ORF61 gene expression.
Discussion
We have identiﬁed a unique spliced VZV transcript, VLT, which
is consistently expressed in latently VZV-infected human TG
neurons. The VLT locus, including splice donor/acceptor sites
and pVLT coding sequence, is highly conserved between wild-
type and vaccine strains of VZV (Supplementary Table 4). A
feature shared by well-characterized latency transcripts of other
αHVs, notably HSV-1 and BHV-1, is their ability to encode
repressive miRNAs13,14. However, in keeping with previous
analyses of human TG34, we found no evidence of miRNAs
encoded within VLT or the wider viral transcriptome. In contrast
to other αHVs, latent VZV also transcribes the lytic ORF63 gene
in a subset of latently infected TGs, suggesting an additional role
for this viral gene in latency or early reactivation. Using a highly
sensitive enriched RNA-Seq method, we found no evidence for
the expression of other VZV genes during latent infection. Nor
did we ﬁnd evidence that HSV-1 latency in human TG involves
the expression of viral transcripts other than the 8.3 kb full-length
and 1.5/2.0 kb spliced HSV-1 LATs and associated miRNAs.
Unlike HSV-1 LAT, VLT encodes a protein (pVLT) whose
expression was strictly dependent on de novo virus DNA repli-
cation (true late kinetics) in lytically VZV-infected cells in vitro
and in shingles skin lesions but was undetectable by IHC during
latency.
The functions of VLT during latency and the VLTly isoforms
expressed during lytic VZV infection remain to be elucidated.
Deletion of VZV ORF61, which would disrupt VLT, does not
affect establishment of quiescent neuronal infection in the cotton
tailed rat35, while a SVV ORF61 deletion mutant, which would
disrupt the putative SVV LAT, could still establish latency in its
natural host36. We have shown that in co-transfected cells VLT
speciﬁcally suppresses the expression of VZV ORF61, an αHV
ICP0 homologue and a promiscuous transactivator of lytic viral
promotors37. The recent development of tractable in vitro cell
Fig. 2 VZV transcriptome proﬁle during lytic and latent infection. Strand-speciﬁc mRNA-seq of lytically VZV-infected ARPE-19 cells and seven latently
VZV-infected human trigeminal ganglia (TG) (Supplementary Table 1). a Circos plots of the VZV genome [purple band; sense and antisense open reading
frames (ORFs) indicated as blue and red blocks, respectively], with internal tracks revealing the lytic (left) and latent (right) transcriptomes using
unenriched (grey track, left panel) and VZV-enriched (black tracks, left and right panels) libraries. Right panel: latent VZV transcriptome of seven TG, with
each track depicting a single specimen. Peaks facing outward from the centre indicate reads mapping to the sense strand, while peaks facing inward
originate from the antisense strand. The y axis is scaled to maximum read depth per library in all cases. b Linear representation of the varicella latency-
associated transcript (VLT) genomic region (black lines in a), with blue and yellow tracks depicting VZV-enriched mRNA-Seq reads originating from the
sense and antisense strands, respectively. Unenriched mRNA-Seq tracks for ARPE-19 cells, and TGs 1 and 2, are superimposed and shown in light blue
(sense) or yellow (antisense), with overlapping regions in medium-blue and orange, respectively. No VZV-mapping reads were obtained from unenriched
sequence data sets generated from TGs 1 and 2. VZV genome coordinates are shown the VZV reference strain Dumas (NC_001348.1); blue and red
arrows indicate previously described VZV ORFs, and light blue boxes indicate the ﬁve VLT exons. Paired-end read data sets were generated with read
lengths of 2 × 34 bp (ARPE-19) or 2 × 76 bp (TG1 and TG2) or 2 × 151 bp (TG3–TG7)
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models25,26 and human fetal DRG organotypic cultures38,39 of
VZV latency and reactivation, although not completely repre-
sentative of the latent TG state, also provides exciting opportu-
nities to explore further VLT function40.
With the availability of effective vaccines, VZV disease is much
reduced in those geographic regions where coverage is high41–43.
However, naturally infected individuals and vaccine recipients
still harbour latent virus (wild type and/or vaccine strains) that
can reactivate to cause disease44. The identiﬁcation of the VLT, 35
years after VZV latency in human sensory ganglia was ﬁrst
described45, provides a signiﬁcant advance in ongoing efforts to
investigate and understand the mechanisms by which VZV
establishes, maintains and reactivates from latency.
Methods
Human clinical specimens. Human TG were obtained at 6:01 h ± 1:47 h (average
± SD) after death (Supplementary Table 1). The brain samples and/or bio samples
were obtained from The Netherlands Brain Bank (NBB), Netherlands Institute for
Neuroscience, Amsterdam (open access: www.brainbank.nl). All Material has been
collected from donors for or from whom a written informed consent for a brain
autopsy and the use of the material and clinical information for research purposes
had been obtained by the NBB. All study procedures were performed in com-
pliance with relevant Dutch laws and institutional guidelines, approved by the local
ethical committee (VU University Medical Center, Amsterdam, project number
2009/148) and was performed in accordance with the ethical standards of the
Declaration of Helsinki. Majority of TG donors had a neurologic disease history
affecting the central nervous system (mainly Alzheimer’s and Parkinson’s disease)
and cause of death was not related to herpesvirus infections. TG biopsies were
either formalin-ﬁxed and parafﬁn-embedded (FFPE) or snap-frozen in liquid
nitrogen and stored at −80 °C. Human fetal DRG were obtained from the Aca-
demic Medical Centre Amsterdam (the Netherlands) according to relevant Dutch
laws and approved by the institutional ethical committee (Erasmus MC, Rotter-
dam, MEC-2017-009). FFPE punch biopsies of one healthy control subject and ﬁve
herpes zoster skin lesions were obtained for diagnostic purposes. Zoster biopsies
were conﬁrmed VZV DNA positive by virus-speciﬁc real-time PCR (qPCR).
According to the institutional 'Opt-Out' system (Erasmus MC, Rotterdam, the
Netherlands), which is deﬁned by the National 'Code of Good Conduct' [Dutch:
Code Goed Gebruik, May 2011], the surplus human herpes zoster FFPE tissues
were available for the current study.
Cells and viruses. Human retinal pigmented epithelium ARPE-19 cells [American
Type Culture Collection (ATCC) CRL-2302] were maintained in 1:1 Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Lonza or Nissui)–Ham’s F12 (Lonza or Sigma-
Aldrich) medium supplemented with 8% heat-inactivated foetal bovine serum
(FBS; Lonza or Sigma-Aldrich) and 0.6 mg/mL L-sodium glutamate (Lonza or
Nacalai). The human MeWo melanoma cell [ATCC HTB-65] was maintained in
DMEM supplemented with 8% FBS and 0.6 mg/mL L-sodium glutamate. Culture
of VZV pOka strain and isolation of cell-free virus have been described pre-
viously46. Low passage clinical isolates VZV EMC-1 and HSV-1 strain F (ATCC
VR-733) were cultured on ARPE-19 cells as described47–49. All cell cultures and
virus infections were performed in a humidiﬁed CO2 incubator at 37 °C.
Nucleic acid extraction from human TG. Approximately one-ﬁfth of snap-frozen
human TG was mechanically dispersed and used for DNA isolation, while four-
ﬁfths of the same specimen was used for RNA isolation. DNA extraction was
performed using the QIAamp DNA Kit (Qiagen) according to the manufacturer’s
instructions. For RNA isolation, samples were homogenized in TRIzol (Invitrogen),
mixed vigorously with 200 µL chloroform and centrifuged for 15 min at 12,000×g
at 4 °C. RNA was isolated from the aqueous phase using the RNeasy Mini Kit,
including on-column DNase I treatment (Qiagen). DNA and RNA concentration
and integrity were analysed using a Qubit Flourometer (ThermoFisher).
RNA extraction from lytic VZV and HSV-1 infections. ARPE-19 cells were
infected with VZV strain EMC-1 by co-cultivation VZV-infected or uninfected
cells at a 1:8 cell ratio and harvested in 1 mL TRIzol at 72 h post-infection (hpi).
Alternatively, semi-conﬂuent ARPE-19 cell layers (75 cm2 ﬂask) were infected with
HSV-1 strain F at a multiplicity of infection of 1 and harvested in 1 mL TRIzol at
24 hpi. RNA isolated as described above was subjected to additional DNase
treatment using the TURBO DNA-free Kit according to the manufacturer’s
instructions (Ambion).
RNA-Seq library preparation and sequencing. Four micrograms of total RNA
was used as input for the SureSelectXT RNA Target Enrichment protocol (Agilent
Technologies G9691 version D0). Here each sample was either enriched for
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Fig. 3 The genomic locus encoding the VZV latency-associated transcript (VLT). a Schematic diagram showing the location and structure of the ﬁve VLT
exons (blue blocks) and introns (blue lines) within the genomic region 101,000–106,000 (coordinates refer to VZV reference strain Dumas; NC_001348.1)
(Supplementary Table 3). b The VLT mRNA sequence including the 5’ untranslated region; start and stop codons are highlighted in red italic, while the
cleavage factor I (CFI)-binding motifs are highlighted in green italic and the canonical polyadenylation signal site (AATAAA) is underlined. Location and
boundaries of VLT exons are indicated by vertical black lines. c The fully translated VLT protein (pVLT), with the sequence of peptide (red) used to produce
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polyadenylated mRNA (captured by oligo-dT beads, as described by the SureSelect
XT protocol) or underwent rRNA-depletion using a NEBNext® rRNA Depletion
Kit [Human/Mouse/Rat] (New England Biolabs) according to the manu-
facturer’s instructions. Subsequent to either procedure, captured/remaining
RNAs were transcribed to produce cDNA. Fragmentation, cDNA second-strand
synthesis, end repair, A-tailing and adapter ligation were performed as described
in the enrichment protocol. Hybridization was performed using a modiﬁed
strategy50,51 that incorporated custom-designed SureSelect RNA bait sets for
both VZV and HSV-1 in the same reaction at reduced concentration (1:10). Bait
sets for VZV (Supplementary Data 1) and HSV-1 (Supplementary Data 2) were
designed at 12× tiling (i.e., each base position in the genome was covered by 12
distinct 120-mer bait sequences) using custom in-house scripts. Hybridization
for 24 h at 65 °C was followed by post-capture washing and optimized PCR-
based library indexing (12 cycles for RNA obtained from lytically infected
cultures, 18 cycles for RNA obtained from TGs). Libraries generated from VZV-
and HSV-1-infected ARPE-19 cells were multiplexed and sequenced using a 75
cycle V2 high-output kit. Subsequently, three TG were multiplexed sequenced
using a 150 cycle V2 mid-output kit followed by a further four TG multiplexed
and sequenced using a 300 cycle V2 high-output kit. The decision to use
increasing read lengths was informed by the initial discovery of VLT and the
desire to better characterize intron splicing.
Transcriptome mapping and de novo transcript reconstruction. Sequence run
data were de-multiplexed using bcl2fastq2 v2.17 under stringent conditions
(--barcode mismatches 0) and yielded between ~31,000,000 and 107,700,000
paired-end reads per sample. Individual sequence data sets were trimmed using the
TrimGalore software (http://www.bioinformatics.babraham.ac.uk/projects/
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ORF63 RNA and VLT expression in consecutive TG sections from individual donors. ns not signiﬁcant; paired Student's t-test. i, j Representative ISH
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trim_galore/) to remove low-quality 3’ ends and mapped to the human genome
(hg19) using the BBMap software (http://sourceforge.net/projects/bbmap/) with
default parameters. Unmapped read pairs were subsequently aligned against VZV
Dumas (NC_001348) and HSV-1 strain 17 (NC_001806) reference genomes
deposited at Genbank using BBMap allowing for properly paired reads only to be
carried forward in the analysis. Extremely high duplication levels (>0.99) were
observed in all enriched libraries generated from TG RNA, an expected feature of
enrichment strategies against ultra-low abundance transcripts. Note, however, that
we are not stating that VLT is a low-abundance transcript within a single cell but
rather that VZV latently infected cells are relatively scarce, thus diluting the
apparent expression level of VLT. To mitigate this, duplicate reads were removed
using the Picard Tools MarkDuplicates software (http://broadinstitute.github.io/
picard). Resulting assemblies were visualized using a combination of Circos52,
Artemis53, Tablet54, SeqMonk (http://www.bioinformatics.babraham.ac.uk/
projects/seqmonk/) software and custom R scripts making use of the Rsamtools
and Gviz software packages.
To conﬁrm that enrichment for viral nucleic acids did not bias relative levels of
viral gene transcription, transcripts per million counts were generated using
FeatureCounts (subread package55,56) and visualized using scatter plots. High
correlation (R2 0.9252–0.9678) between enriched and unenriched transcriptomes
were observed for both HSV-1 (n= 2 biological replicates) and VZV (n= 1), as
shown in Supplementary Fig. 1.
For de novo transcript reconstruction, VZV-speciﬁc mapping read pairs for
each TG were extracted from BAM ﬁles and converted to raw fastq format for
input into Trinity57. Trinity enables transcript reconstruction and, while limited in
this case by the scarcity of VZV reads, was able to merge overlapping reads to
produce transcript isoforms that, when mapped to the VZV reference genome
using BBmap, spanned the four major introns observed in the VLT.
MicroRNA sequencing (miRNASeq) and qPCR proﬁling. miRNASeq libraries
were prepared from 1 µg of total RNA, isolated from human TG and lytically VZV-
and HSV-1-infected ARPE-19 cells using the NEBNext® small RNA Library Prep
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Set for Illumina® according to the manufacturer’s instructions. Libraries underwent
75 bp single-end sequencing using an Illumina NextSeq prior to demultiplexing (as
outlined above). Sequence reads were adaptor-trimmed using TrimGalore and size
selected using BBduk (provided with BBmap) so that only sequence reads
between 17 and 26 bases in length were retained. These were mapped against
VZV strain Dumas and the HSV-1 strain 17 reference genomes as well as miRDB
using ShortStack (--dicermin 18 --mincov 1 --mismatches 2 --foldsize 200). No
putative VZV miRNAs could be detected in either latently infected TGs or
lytically infected ARPE-19 cells. By contrast, canonical HSV-1 miRNAs could be
detected in both latently infected TGs and lytically infected ARPE-19 cells at
high abundance.
cDNA synthesis and qPCR. cDNA synthesis was performed as described18 using
2.0–11.7 µg [6.7 µg ± 0.64 (average ± SEM)] of TG-derived total RNA or 5 µg of
cell-culture-derived DNase-free RNA and Superscript III reverse transcriptase
(Invitrogen) with oligo(dT)12-18 primers (Invitrogen). Taqman qPCR was per-
formed in triplicate on DNA and cDNA using Taqman 2× PCR Universal Master
Mix (Applied Biosystems) with primer/probe pairs speciﬁc for VZV ORF62,
ORF63 and the VLT exon 2→3, 3→4, A→1, B→1 and C→1 junctions and HSV-1
DNA58 and LAT, (all from Eurogentec), β-actin (Applied Biosystems) and the
human single copy gene hydroxymethylbilane synthase (Supplementary Table 5).
Commercially quantiﬁed VZV and HSV-1 DNA stocks (Advanced Biotechnolo-
gies) and plasmids encoding VZV DNA amplicons (ORF63 and VLT; described in
'Plasmid construction' section below) were used to standardize qPCR reactions and
used as positive control in each qPCR. RT-qPCR data were presented as absolute
transcript copy number per 100 ng RNA (Fig. 4e and Supplementary Figs. 7a and
9a), relative transcript levels deﬁned as 2−(Ct-value VZV gene−Ct-value β-actin) (Fig. 4d, f
and Supplementary Figs. 7b−d and 11) and fold change in gene expression using
the 2−ΔΔCt method59 in which transcript levels were normalized to β-actin and a
reference sample (Figs. 5c and 6a).
Sequence analysis of lytic and latent VLT isoforms. PCR was performed on
cDNA obtained from ﬁve human TG donors [TGs 2, 3, 4, 6 and 7, which expressed
the highest VLT levels (Supplementary Table 1)] using Pfu Ultra II Fusion HS
DNA Polymerase (Stratagene) and primers ORF61-13 and VLT_exon5-Rv (Sup-
plementary Table 5). 5’RACE and 3’RACE were performed using the SMARTerTM
RACE cDNA Ampliﬁcation Kit (Clontech) according to the manufacturer’s
instructions using total RNA extracted from VZV pOka-infected MeWo cells. PCR
was performed using KOD-Plus-Ver.2 DNA Polymerase (Toyobo Life Science)
templated with 5’RACE ready cDNA using Universal Primer A Mix and
ORF61R626AS or pOka104778R or 3’RACE ready cDNA using Universal Primer
A Mix and ORF61R626AS (Supplementary Table 5). Alternatively, 5’RACE was
performed using the FirstChoiceTM RLM-RACE Kit (Ambion) according to the
manufacturer’s instructions, using 10 µg of total RNA obtained from VZV EMC-1-
infected ARPE-19 cells. Nested PCR was performed using Pfu Ultra II Fusion HS
DNA Polymerase (Stratagene) and 40 cycles of ﬁrst round ampliﬁcation using
5’RACEout_Fw–VLT2-3_Rv primers, followed by 40 cycles of second round
ampliﬁcation using 5’RACEinn_Fw–VLT2_Rv primers (Supplementary Table 5).
PCR products were cloned into the pCRTM4-TOPO® TA vector (Thermo Fisher
Scientiﬁc) after addition of 3’A overhang using AmpliTaq Gold DNA polymerase
(Thermo Fisher Scientiﬁc) or Takara Ex Taq® (Takara Bio) and used to transform
One Shot® TOP10 competent Escherichia coli. Plasmid DNA was extracted using
the QIAprep Spin Miniprep Kit (Qiagen), ampliﬁed by PCR using M13Fw and
M13Rv primers (Supplementary Table 5) and Pfu Ultra II Fusion HS DNA
Polymerase (Stratagene). Plasmid DNAs or puriﬁed PCR products were sequenced
on the ABI Prism 3130 XL Genetic Analyzer using the BigDye v3.1 Cycle
Sequencing Kit (both Applied Biosciences) and M13Fw and M13Rv primers.
Resultant FASTA sequences were aligned the VZV reference genome Dumas using
BBmap, as outlined above. Resultant assemblies were inspected alongside RNA-Seq
data using IGV60.
In situ hybridization. To select for VZV and HSV-1 DNA-positive TG tissue
areas, DNA was isolated from three consecutive 5 µm FFPE tissue sections using
the QIAamp DNA FFPE Tissue Kit and analysed by the respective virus-speciﬁc
qPCR assays. Subsequently, viral DNAPOS FFPE TG specimens, human fetal
DRG (negative control) and human zoster skin biopsies were analysed by in situ
hybridization (ISH) using the RNAScope 2.0 Red Kit (Advanced Cell Diag-
nostics) according to the manufacturer’s instructions. In brief, deparafﬁnized 5
µm tissue sections were incubated with probes designed to cover VZV ORF63
and VLT exons 2–5. The probes for the human transcript POLR2A and ubi-
quitin C were used as positive controls and probes speciﬁc for the bacterial
transcript DAPB were used as negative controls. All probes were designed and
produced by Advanced Cell Diagnostics. FastRed was used as substrate to
visualize the ISH signal and stained slides were counterstained with haema-
toxylin and mounted in Ecomount (Biocare Medical). In some experiments, TG
sections were incubated with DNase I (Qiagen) or RNAse [Ribonuclease A (25
µg/mL)+T1 (25 units/mL; both Thermo Fisher Scientiﬁc) diluted in 1×TBS-t],
after pre-treatment step #3 for 1 h at 40 °C. To determine the ratio of VZV and
HSV-1 transcript expressing TG neurons, slides were scanned using the
Nanozoomer 2.0 HT (Hamamatsu) and scored in Adobe Photoshop CS6
(Adobe). Twelve TG from distinct donors were analysed for VZV ORF63
transcript and VLT and 10 TG for HSV-1 LAT, with on average 664 neurons/
section (range: 420–1561) and 1–2 sections per TG. Two herpes zoster skin
biopsies from distinct donors were analysed with 2–3 sections per donor for each
staining.
Determination of kinetic class of VZV transcripts. ARPE-19 cells (2 × 105 cells)
were infected with pOka VZV cell-free virus (103 plaque-forming units) with and
without PFA (200 µg/mL) for 24 h at 37 °C. Total RNA was isolated from cells
using NucleoSpin RNA in combination with the NucleoSpin RNA/DNA buffer set
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(Macherey-Nagel) according to the manufacturer’s instructions. Binding DNA was
ﬁrst eliminated from the column in 100 µL DNA elution buffer, the column was
treated with recombinant DNase I (5 units/100 µL; Roche Diagnostics) for 1 h at
37 °C and ﬁnally RNA was eluted in 60 µL nuclease-free water. cDNA was syn-
thesized with 10.4 µL of total RNA and anchored oligo(dT)18 primer in a 20 µL
reaction using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diag-
nostics). qPCR following a dissociation curve analysis was performed as described
previously25 using SYBR Select Master Mix in a StepOnePlus Real-time PCR
system (Thermo Fisher Scientiﬁc). The primer sets for β-actin and VZV ORF61
and ORF49 genes were described previously25 and primers for VZV ORF29
(ORF29F2381 and ORF29R2440) and VLT (VLTexon1F and VLTexon2R) are
presented in Supplementary Table 5.
Plasmid construction. The VLT coding sequence (102,468–104,818, excluding
introns indicated in Supplementary Table 3) and ORF61 and ORF63 coding
sequences were ampliﬁed by PCR of cDNA prepared from pOka-infected MeWo
cells showing >80% cytopathic effect using the primer sets VLTup22ecoF and
VLT-FLAGxhoR, ORF61up20ecoF and ORF61SalR or NPup20ecoF and
ORF63xhoR, respectively (Supplementary Table 5). Products were digested with
EcoRI and XhoI (VLT and ORF63) or EcoRI and SalI (ORF61) restriction
enzymes and subsequently cloned into pCAGGS-MCS-puro (CAG.Empty) via
EcoRI and XhoI sites. The resulting VLT-, ORF61- and ORF63-expressing
plasmids were named as follows: CAG.VLT-FLAG, CAG.ORF61, and CAG.
ORF63, respectively. The CAG.VLT(ATA)-FLAG plasmid, in which the ATG
start codon of VLT ORF was mutated to ATA to prevent pVLT expression, was
generated using primer VLT-G3A with a QuickChange Lightning Multi Site-
Directed Mutagenesis Kit (Agilent Technologies) according to the manu-
facturer’s recommendation based on the CAG.VLT-FLAG. All primers used to
construct VZV gene expression plasmids are listed in Supplementary Table 5.
The pCAGGS plasmid61 was generous gift from Dr. Jun-ichi Miyazaki (Osaka
University, Japan). The pcDNA.ORF62 was a generous gift from Dr. Yasuyuki
Gomi (Research Foundation for Microbial Diseases, Osaka University).
Generation of rabbit anti-pVLT and -IE63 antibodies. Anti-VLT protein (pVLT)
antibody was generated by Sigma-Aldrich by immunizing a rabbit with a synthetic
peptide encoding the ﬁrst 19 amino acids of pVLT (MPRLLRDRIAGIPNRVRTY;
Fig. 3c). The antibody was puriﬁed using pVLT peptide-conjugated NHS (N-
hydroxysuccinimide)-activated sepharose (GE Healthcare Life Sciences). For
probing of ORF63 (NP_040185.1), an anti-IE63 antibody was also generated by
Sigma-Aldrich by immunizing a rabbit with GST-IE63 protein as described for
anti-IE61 antibody62. Brieﬂy, GST-IE63 protein was expressed in and puriﬁed from
E. coli BL21 transformed with pGEX-IE63, in which the entire DNA fragment
except the ﬁrst ATG (i.e., ORF63 nucleotide positions 4–837) was cloned into
pGEX6P-1 bacterial expression vector (GE Healthcare). The anti-IE63 antibody
was puriﬁed using GST-conjugated NHS-activated sepharose for depleting anti-
GST antibody and GST-IE63-conjugated NHS-activated sepharose.
Immunoﬂuorescent staining and confocal microscopy of cells. The following
primary mouse monoclonal antibodies directed to the indicated proteins were used:
VZV IE62 (1:100 dilution; generous gift from Dr. Jürgen Haas (University of
Edinburgh, UK) and Dr. Stipan Jonjić (Faculty of Medicine, Rijeka, Croatia))63,
VZV glycoprotein E (1:200 dilution; MAB8612, Millipore) and DYKDDDDK tag
(FLAG tag) (1:100 dilution; Clone 1E6, WAKO). Alexa Fluor 488- and Alexa Fluor
594-conjugated goat-anti-rabbit and -anti-mouse IgG (1:250 dilution; Thermo
Fisher Scientiﬁc) were used as secondary polyclonal antibodies, respectively.
Hoechst 33342 (Sigma-Aldrich) was used for nuclear staining. Confocal micro-
scopic analysis were performed as previously described62,64.
IHC and immunoﬂuorescence on skin biopsies. Deparafﬁnized and rehydrated
5 µm FFPE sections of human herpes zoster skin lesions and healthy control skin
were subjected to heat-induced antigen retrieval with citrate buffer (pH= 6.0),
blocked and incubated with mouse anti-VZV IE63 (1:1500 dilution; kindly
provided by Dr. Sadzot-Delvaux; Liege, Belgium)65, rabbit anti-pVLT (1:100
dilution) or isotype control antibodies overnight at 4 °C. Sections were subse-
quently incubated with biotinylated secondary goat-anti-rabbit immunoglobulin
(Ig) or goat-anti-mouse Ig and streptavidin-conjugated horseradish peroxidase
(all from Dako) for 1 h at room temperature. Signal was visualized using 3-
amino-9-ethylcarbazole and counterstained with haematoxylin (Sigma-Aldrich).
For immunoﬂuorescent staining, Alexa Fluor 488- and Alexa Fluor 594-
conjugated goat-anti-mouse and goat-anti-rabbit antibodies (all 1:250 dilution)
were used, and sections were mounted with Prolong Diamond antifade
mounting medium with 4,6-diamidino-2-phenylindole. Confocal microscopic
analysis was performed as described64.
Plasmid co-transfection, RT-qPCR and immunoblotting. Plasmid co-
transfection was performed using PEImax (molecular weight 40,000) (Poly-
sciences, Inc.). High potency linear polyethyleneimine was dissolved in water (1
mg/mL), adjusted to pH= 7 with NaOH, ﬁltered through an 0.22 µm ﬁlter and
stored in aliquots at −20 °C until use. CAG.Empty, CAG.VLT-FLAG or CAG.
VLT(ATA)-FLAG (2 µg) with CAG.ORF61, pcDNA.ORF62 and CAG.ORF63 (1
µg) were diluted in knockout DMEM/F12 media (Thermo Fisher Scientiﬁc) (50
µL) and PEImax solution (6 µL) were diluted in knockout DMEM/F12 media
(50 µL), then both diluent were mixed, left at room temperature for 10–15 min to
form polyplexes and transfected into ARPE-19 cell (1 × 105 cells/well in an 12-
well plate). Culture medium was changed at 16 h post-transfection and cultured
for another 48 h. Cells were harvested and aliquoted into two fractions. Total
RNA extraction from one fraction of transfectants, cDNA synthesis and relative
qPCR were performed as described in 'Determination of kinetic class of VZV
transcripts' section using the FavorPrep Blood/Cultured Cell Total RNA Mini
Kit (FAVORGEN BIOTECH) instead of NucleoSpin RNA. The primer sets for
VZV ORF62 (ORF62F2016 and ORF62R2083) and VLT (VLTexon2F and
VLTexon2R-2) are presented in Supplementary Table 5. Immunoblotting was
performed using a rabbit polyclonal antibody against VZV IE61 or IE63, mouse
monoclonal antibodies against alpha-tubulin (B-5-1–2; Sigma-Aldrich) and
VZV IE62 (clone 2-B; generous gift from Dr. Yasuyuki Gomi (Research Foun-
dation for Microbial Diseases, Osaka University))66 or DYKDDDDK (FLAG) tag
(WAKO) for pVLT detection as described previously62. Uncropped images of
immunoblotting are shown in Supplementary Figure 13.
Data availability. All sequencing runs were performed using an Illumina NextSeq
550 and all demultiplexed fastq data set are available via the European Nucleotide
Archive under study accession number PRJEB23238. RACE-derived VLTly
sequences are available through Genbank under accession numbers
MG191301–MG191319.
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